The impact of CRISPR–Cas9 on target identification and validation

•Cas9 has utility across gene editing especially for rapid knock-out (KO) generation.•The D10A nickase mutant may boost rates of homologous recombination.•The infrastructure developed for shRNA can be redeployed in sgRNA drop out screens.•sgRNA KO screens may overcome many of the issues with large-s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug discovery today 2015-04, Vol.20 (4), p.450-457
1. Verfasser: Moore, Jonathan D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 457
container_issue 4
container_start_page 450
container_title Drug discovery today
container_volume 20
creator Moore, Jonathan D.
description •Cas9 has utility across gene editing especially for rapid knock-out (KO) generation.•The D10A nickase mutant may boost rates of homologous recombination.•The infrastructure developed for shRNA can be redeployed in sgRNA drop out screens.•sgRNA KO screens may overcome many of the issues with large-scale shRNA screens.•Cas9 enables rapid gene editing in vivo: KO animals can be made in a few months. The addition of an RNA-guided nuclease, Cas9, to the gene editing toolbox has increased the accessibility of gene editing technologies by greatly simplifying the design of editing reagents. Only a single 75–100 nucleotide RNA is required to guide Cas9 to the target gene of interest, which has meant that the established infrastructure of short-hairpin RNA interference screen could be readily adapted to genome-wide knock out screens. Cas9-based editing technology should streamline the generation of animal and cell-line models, make the generation of activity-dead mutations in target validation routine, and enable the discovery of a new generation of targets across therapeutic areas.
doi_str_mv 10.1016/j.drudis.2014.12.016
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1691601584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359644614004875</els_id><sourcerecordid>1691601584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-c50da113a0e289d1ca039e32d58043723fef466031e5b3928b6ef3f3a2c6f3243</originalsourceid><addsrcrecordid>eNp9UMtKw0AUHUSxWv0DkSzdNM67yUaQ4KNQUGpdD9OZOzqlSepMUnDnP_iHfompqS7d3MfhnHu4B6EzglOCibxcpja01seUYsJTQtMO3ENHJBtnI5Exut_NTOQjybkcoOMYlxgTmgt5iAZUiDHlWB6hYv4KiS_X2jRJ7ZJiNnl6nH19fBY65kldJY0OL9Ak3kLVeOeNbnyH6somG73y9mc9QQdOryKc7voQPd_ezIv70fThblJcT0dGcN50FVtNCNMYaJZbYjRmOTBqRYY5G1PmwHEpMSMgFiyn2UKCY45paqRjlLMhuujvrkP91kJsVOmjgdVKV1C3URGZE4mJyLZU3lNNqGMM4NQ6-FKHd0Ww2sanlqqPT23jU4SqDuxk5zuHdlGC_RP95tURrnoCdH9uPAQVjYfKgPUBTKNs7f93-AbwfYH5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1691601584</pqid></control><display><type>article</type><title>The impact of CRISPR–Cas9 on target identification and validation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Moore, Jonathan D.</creator><creatorcontrib>Moore, Jonathan D.</creatorcontrib><description>•Cas9 has utility across gene editing especially for rapid knock-out (KO) generation.•The D10A nickase mutant may boost rates of homologous recombination.•The infrastructure developed for shRNA can be redeployed in sgRNA drop out screens.•sgRNA KO screens may overcome many of the issues with large-scale shRNA screens.•Cas9 enables rapid gene editing in vivo: KO animals can be made in a few months. The addition of an RNA-guided nuclease, Cas9, to the gene editing toolbox has increased the accessibility of gene editing technologies by greatly simplifying the design of editing reagents. Only a single 75–100 nucleotide RNA is required to guide Cas9 to the target gene of interest, which has meant that the established infrastructure of short-hairpin RNA interference screen could be readily adapted to genome-wide knock out screens. Cas9-based editing technology should streamline the generation of animal and cell-line models, make the generation of activity-dead mutations in target validation routine, and enable the discovery of a new generation of targets across therapeutic areas.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2014.12.016</identifier><identifier>PMID: 25572406</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Bacterial Proteins - genetics ; Bacterial Proteins - metabolism ; Clustered Regularly Interspaced Short Palindromic Repeats ; CRISPR-Cas Systems ; Drug Discovery - methods ; Endonucleases - genetics ; Endonucleases - metabolism ; Gene Expression Regulation ; Gene Targeting - methods ; Genetic Predisposition to Disease ; Humans ; Phenotype</subject><ispartof>Drug discovery today, 2015-04, Vol.20 (4), p.450-457</ispartof><rights>2015</rights><rights>Copyright © 2015. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-c50da113a0e289d1ca039e32d58043723fef466031e5b3928b6ef3f3a2c6f3243</citedby><cites>FETCH-LOGICAL-c544t-c50da113a0e289d1ca039e32d58043723fef466031e5b3928b6ef3f3a2c6f3243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1359644614004875$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25572406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moore, Jonathan D.</creatorcontrib><title>The impact of CRISPR–Cas9 on target identification and validation</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>•Cas9 has utility across gene editing especially for rapid knock-out (KO) generation.•The D10A nickase mutant may boost rates of homologous recombination.•The infrastructure developed for shRNA can be redeployed in sgRNA drop out screens.•sgRNA KO screens may overcome many of the issues with large-scale shRNA screens.•Cas9 enables rapid gene editing in vivo: KO animals can be made in a few months. The addition of an RNA-guided nuclease, Cas9, to the gene editing toolbox has increased the accessibility of gene editing technologies by greatly simplifying the design of editing reagents. Only a single 75–100 nucleotide RNA is required to guide Cas9 to the target gene of interest, which has meant that the established infrastructure of short-hairpin RNA interference screen could be readily adapted to genome-wide knock out screens. Cas9-based editing technology should streamline the generation of animal and cell-line models, make the generation of activity-dead mutations in target validation routine, and enable the discovery of a new generation of targets across therapeutic areas.</description><subject>Animals</subject><subject>Bacterial Proteins - genetics</subject><subject>Bacterial Proteins - metabolism</subject><subject>Clustered Regularly Interspaced Short Palindromic Repeats</subject><subject>CRISPR-Cas Systems</subject><subject>Drug Discovery - methods</subject><subject>Endonucleases - genetics</subject><subject>Endonucleases - metabolism</subject><subject>Gene Expression Regulation</subject><subject>Gene Targeting - methods</subject><subject>Genetic Predisposition to Disease</subject><subject>Humans</subject><subject>Phenotype</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UMtKw0AUHUSxWv0DkSzdNM67yUaQ4KNQUGpdD9OZOzqlSepMUnDnP_iHfompqS7d3MfhnHu4B6EzglOCibxcpja01seUYsJTQtMO3ENHJBtnI5Exut_NTOQjybkcoOMYlxgTmgt5iAZUiDHlWB6hYv4KiS_X2jRJ7ZJiNnl6nH19fBY65kldJY0OL9Ak3kLVeOeNbnyH6somG73y9mc9QQdOryKc7voQPd_ezIv70fThblJcT0dGcN50FVtNCNMYaJZbYjRmOTBqRYY5G1PmwHEpMSMgFiyn2UKCY45paqRjlLMhuujvrkP91kJsVOmjgdVKV1C3URGZE4mJyLZU3lNNqGMM4NQ6-FKHd0Ww2sanlqqPT23jU4SqDuxk5zuHdlGC_RP95tURrnoCdH9uPAQVjYfKgPUBTKNs7f93-AbwfYH5</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Moore, Jonathan D.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>The impact of CRISPR–Cas9 on target identification and validation</title><author>Moore, Jonathan D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-c50da113a0e289d1ca039e32d58043723fef466031e5b3928b6ef3f3a2c6f3243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Bacterial Proteins - genetics</topic><topic>Bacterial Proteins - metabolism</topic><topic>Clustered Regularly Interspaced Short Palindromic Repeats</topic><topic>CRISPR-Cas Systems</topic><topic>Drug Discovery - methods</topic><topic>Endonucleases - genetics</topic><topic>Endonucleases - metabolism</topic><topic>Gene Expression Regulation</topic><topic>Gene Targeting - methods</topic><topic>Genetic Predisposition to Disease</topic><topic>Humans</topic><topic>Phenotype</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moore, Jonathan D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moore, Jonathan D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of CRISPR–Cas9 on target identification and validation</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>20</volume><issue>4</issue><spage>450</spage><epage>457</epage><pages>450-457</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>•Cas9 has utility across gene editing especially for rapid knock-out (KO) generation.•The D10A nickase mutant may boost rates of homologous recombination.•The infrastructure developed for shRNA can be redeployed in sgRNA drop out screens.•sgRNA KO screens may overcome many of the issues with large-scale shRNA screens.•Cas9 enables rapid gene editing in vivo: KO animals can be made in a few months. The addition of an RNA-guided nuclease, Cas9, to the gene editing toolbox has increased the accessibility of gene editing technologies by greatly simplifying the design of editing reagents. Only a single 75–100 nucleotide RNA is required to guide Cas9 to the target gene of interest, which has meant that the established infrastructure of short-hairpin RNA interference screen could be readily adapted to genome-wide knock out screens. Cas9-based editing technology should streamline the generation of animal and cell-line models, make the generation of activity-dead mutations in target validation routine, and enable the discovery of a new generation of targets across therapeutic areas.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>25572406</pmid><doi>10.1016/j.drudis.2014.12.016</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1359-6446
ispartof Drug discovery today, 2015-04, Vol.20 (4), p.450-457
issn 1359-6446
1878-5832
language eng
recordid cdi_proquest_miscellaneous_1691601584
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Bacterial Proteins - genetics
Bacterial Proteins - metabolism
Clustered Regularly Interspaced Short Palindromic Repeats
CRISPR-Cas Systems
Drug Discovery - methods
Endonucleases - genetics
Endonucleases - metabolism
Gene Expression Regulation
Gene Targeting - methods
Genetic Predisposition to Disease
Humans
Phenotype
title The impact of CRISPR–Cas9 on target identification and validation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T15%3A03%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20CRISPR%E2%80%93Cas9%20on%20target%20identification%20and%20validation&rft.jtitle=Drug%20discovery%20today&rft.au=Moore,%20Jonathan%20D.&rft.date=2015-04-01&rft.volume=20&rft.issue=4&rft.spage=450&rft.epage=457&rft.pages=450-457&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2014.12.016&rft_dat=%3Cproquest_cross%3E1691601584%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1691601584&rft_id=info:pmid/25572406&rft_els_id=S1359644614004875&rfr_iscdi=true